NASDAQ · NRIX
Nurix Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarThe next earnings date for NRIX has not been announced yet.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Nov 2026 | $-0.46 | $-0.17 | $-0.79 | 6 |
| Feb 2027 | $-0.47 | $-0.38 | $-0.57 | 3 |
| May 2027 | $-0.50 | $-0.38 | $-0.59 | 3 |
| Aug 2027 | $-0.47 | $-0.38 | $-0.61 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews- Zacks · Oct 22, 1:35 PM EDTRoche's 9M 2026 Sales Rise on Strong Drug Demand, Pipeline AdvancesRoche's sales rise 6% at constant exchange rates in the first nine months of 2026, as key drug growth offsets legacy product declines and pipeline advances.
- Zacks · Oct 19, 9:08 AM EDTCan KYMR's Targeted Protein Degradation Pipeline Drive Future Growth?Kymera Therapeutics advances its targeted protein degradation pipeline, with KT-621 trials in atopic dermatitis and asthma marking key milestones amid competition in the field.
- RTTNews · Oct 13, 3:47 AM EDTNurix Swings To Profit In Q3 As Roche Deal Drives Revenue Surge(RTTNews) – Nurix Therapeutics, Inc. (NRIX), a clinical-stage biopharmaceutical company, reported third-quarter 2026 financial results alongside updates on its clinical pipeline and business collaborations.
- RTTNews · Oct 13, 3:28 AM EDTNurix Therapeutics Swings To Profit In Q3 On Roche Licensing Revenue(RTTNews) – Nurix Therapeutics, Inc. (NRIX), clinical-stage biopharmaceutical company, reported a swing to profit in the third quarter from a loss in the year-ago period, primarily reflecting a major licensing revenue from its collaboration with Swiss drug major Roche Holding AG
- Zacks · Oct 12, 4:25 PM EDTNurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass EstimatesNurix Therapeutics (NRIX) delivered earnings and revenue surprises of +944.64% and +383.11%, respectively, for the quarter ended August 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Oct 9, 1:37 PM EDTWeekly Buzz: RHHBY, NVS, PFE Win FDA Nod; CRBU Scales Back; PCVX, ABBV Report Positive Trial Data(RTTNews) – This week, biopharmaceutical companies saw a busy week of regulatory decisions, strategic partnerships and clinical developments, alongside pipeline setbacks and workforce reductions.
- RTTNews · Oct 7, 5:06 AM EDTNurix Initiates Phase 1b/2 Bexobrutideg Trial In Lymphocytic Leukemia(RTTNews) – Nurix Therapeutics, Inc. (NRIX), a clinical-stage biopharmaceutical company, announced on Wednesday that it has enrolled the first patient in a Phase 1b/2 study evaluating bexobrutideg in combination with venetoclax in chronic lymphocytic leukemia/small lymphocytic ly
- RTTNews · Oct 5, 8:36 AM EDTNurix Extends Gilead Oncology Research Collaboration For Two Years(RTTNews) – Nurix Therapeutics, Inc. (NRIX) on Monday announced that it and Gilead Sciences (GILD) have agreed to extend the research term for an undisclosed oncology program under their strategic collaboration by an additional two years.
- Zacks · Oct 1, 3:35 AM EDTPrecigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock?Precigen (PGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- Zacks · Sep 21, 5:35 PM EDTAnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue EstimatesAnaptysBio (ANAB) delivered earnings and revenue surprises of +76.09% and +3.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Sep 10, 9:51 AM EDTHere's Why You Should Add NRIX Stock to Your Portfolio NowNurix is developing bexobrutideg in CLL, while Roche's $2.3B deal and new studies support its potential in cancer, immunology and neurology.
- Zacks · Sep 9, 12:00 PM EDTNurix Therapeutics (NRIX) Upgraded to Buy: Here's WhyNurix Therapeutics (NRIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Nurix Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.